Erbitux™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

Listen to the audio transcription of the CMI leaflet.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer. In combination with infusional 5-fluorouracil/folinic acid plus irinotecan. In combination with irinotecan in patients who are refractory to first-line chemotherapy. In first-line in combination with FOLFOX. As a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy. (See CLINICAL TRIALS) Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck. In combination with radiation therapy for locally advanced disease. In combination with platinum-based chemotherapy for recurrent and/or metastatic disease.

Source: ARTG

• Shelf lifetime is 48 Months
• Store at 2 to 8 degrees Celsius
• Do not Freeze; Refrigerate

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Injection, intravenous infusion
• Intravenous
• Clear to slightly opalescent, colourless to yellowish solution.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 1 x 20mL vial

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under the following PBS item codes:

• 7242E (Opens in new tab)
• 4436L (Opens in new tab)
• 7223E (Opens in new tab)
• 7240C (Opens in new tab)
• 12821T (Opens in new tab)
• 4312Y (Opens in new tab)
• 12816M (Opens in new tab)
• 4731B (Opens in new tab)
• 10262D (Opens in new tab)
• 12817N (Opens in new tab)
• 7273T (Opens in new tab)
• 12820R (Opens in new tab)
• 10265G (Opens in new tab)
• 4435K (Opens in new tab)

Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Cetuximab

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).